DoseGear research brief
No additional research overview is listed.
DG Peptide Protocols
Well StudiedWeight LossGrowth Hormone
MK-677
Ibutamoren
Ghrelin Receptor Agonist | Growth Hormone Secretagogue
Research overview
Mechanism of action
Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns.
Compound background
Development & research timeline
Study windows describe what researchers measured, not when an individual should expect a result.
Origin & development
Synthetic nonpeptide growth-hormone secretagogue, also called ibutamoren.
What it is researched for
Growth-hormone and IGF-axis research through ghrelin-receptor agonism.
Research observation window
Not reported within the injectable-vial scope.
Reference data
Lyophilized vial injectable protocols
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
No sourced lyophilized-vial injectable protocol is listed for this profile.
Safety context
Reported side effects
- Appetite stimulation (>50% of users)
- Water retention (30-40%)
- Lethargy (20-30%)
- Fasting glucose elevation (5-15mg/dL)
- Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications & cautions
- Heart disease or congestive heart failure
- Diabetes or pre-diabetes
- Active cancer
- Severe cardiovascular disease
- Pregnancy or breastfeeding
Scientific references
No additional scientific references are listed for this profile.
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.